The PennZone

  • Home
  • Business
  • Health
  • Financial
  • Construction
  • Entertainment
  • Arts
  • Automotive
  • Music

Beneficience.com Legacy PR Announces Dr. Burd Renowned Diabetes Scientist, Biochemist-entrepreneur and Dexcom Founder, client
The PennZone/10216335

Trending...
  • SMS Launches Real-Time Fiber-Optic Monitoring for Critical Infrastructure
  • Safe Health Zones: A Global Breakthrough to Protect Night-Shift Workers from Preventable Harm
  • purelyIV Expands Wellness Services with Flu/COVID Testing and Menopause Coaching & Treatment
Beneficience Com Announces Dr John Burd, Renowned Dr John Burd Lysulin© Dr Burd Wonder Spray Skin Rescue 8oz Skin Rescue Lysulin© Products Beneficience.com Legacy PR
Dr. Burd is a renowned diabetes scientist and biochemist and Founder of Dexcom, the worldwide leader in Continuous Glucose Monitoring (CGM) systems. Get to know him and what good he is doing in the world, and for whom his life work benefits.

SAN DIEGO - PennZone -- About John Burd, PhD:

Dr. Burd is Founder & CEO of Lysulin, Inc and Wonder Spray, llc.  In 2017 Dr. Burd founded Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes.   The first patented product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications.  In 2019 Dr. Burd founded Wonder Spray, llc to provide relief for a variety of ailments and skincare problems using a natural and safe chemical that is used by white blood cells to kill all pathogens.

Dr. Burd was previously President & CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes.  In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million.  In 2020 DexCom had a market cap of over $40 billion.  From 1999 to 2004 Dr. Burd was a General Partner of Windamere Venture Partners.

Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duetâ Diabetes Control System to healthcare professionals and the In ChargeÔ Diabetes Control System to the diabetes self-testing market.  LXN was sold to Johnson and Johnson in 2000.

More on The PennZone
  • Winzele: A Trusted Isolation Transformer Manufacturer
  • Luxury Mediterranean Estate in Gotha Sells for $1.52 Million, Closing $45,000 Over Asking
  • ZEELOOL's Black Friday Sale Starts Early with Up to 80% Off Frames
  • UV Weathering Test Chamber vs Xenon Arc Test Chamber: What's the Right Solution for Your Products
  • Emeritus Addresses Hospital Bed Shortages with Smart Storage Solutions

Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician's office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company's operations, including research and development, marketing, sales and finance.  MAST Immunosystems was purchased by Hitachi Chemical in 1997.  Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).

Dr. Burd has authored and co-authored over 45 articles and his work in the medical and biotechnology field has led to the filing and ownership of forty patents and the development of many innovative medical products.  He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin.  In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.

Disclaimer: Dr. Burd's published product statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

JOHN F. BURD, Ph.D.

Founder & CEO Lysulin, Inc and Wonder Spray, llc.

More on The PennZone
  • Fulton County & Grow Your World Amplify Atlanta Youth Through the Youth Audio Collective
  • 2026 Oscars Betting Odds: One Battle After Another Favored for Best Picture
  • Allen Field Co., Inc. Components Selected for Esko ArtiosCAD 3D Component Library
  • Thirteen Reasons Why Gyminny Kids Is San Diego's Best Gymnastics Gym
  • Heritage At Manalapan - A New Luxury Single Family Home Community Coming Late 2025

4930 Bradshaw Court, San Diego, CA  92130
Phone: 619-992-2873

Website: Promotes Healthy Insulin Function and helps maintain healthy A1c (lysulin.com)

Learn more about Dr. Burd's products below...

Insulin resistance: https://www.youtube.com/watch?v=rdiHqff3EY8



Lysulin video:  https://www.youtube.com/watch?v=PK3CkMty6RE



Running A1c test: https://tinyurl.com/y379jbla

Wonder Spray:
https://www.youtube.com/channel/UCYFv1jgn3LmADcZklzLbMHA/videos

Follow Burd's PR News at http://Beneficience.com

MEDIA REQUESTS + MEDIA BOOKING: Dr. Burd is available for relevant events, speaking engagements, radio, podcast, television and media opportunities, news interviews, et als. Burd's media contact information is available now by request online at Beneficience.com Legacy PR at https://beneficience.com/?s=Dr.+John+Burd

Contact
Dr. Tracey Bond, MPRL
Certified Publicist of Record
for John Burd, PhD
***@beneficience.com


Source: Beneficience.com Legacy PR
Filed Under: Business, Health

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Taking on the Multi-Billion-Dollar Swipe Industry: AI Curates Who You Meet—IRL over brunch
  • Safe Health Zones: A Global Breakthrough to Protect Night-Shift Workers from Preventable Harm
  • Cartwheel Signs Letter of Intent to License Clearsight Therapeutics' Novel Pink Eye Treatment for 2027 Portfolio Expansion
  • Vet Maps Launches National Platform to Spotlight Veteran-Owned Businesses and Causes
  • Diamond Wealth Advisors Experience the New York Stock Exchange and Ring the Closing Bell
  • $114.6 Million in Revenues, Up 54%: Uni-Fuels Holdings (N A S D A Q: UFG) Accelerates Global Expansion Across Major Shipping Hubs as Demand Surges
  • Dental Care Solutions Unveils New Website for Enhanced Patient Engagement
  • TradingHabits.com Launches to Support Day Trader Well-being
  • $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
  • SMS Launches Real-Time Fiber-Optic Monitoring for Critical Infrastructure
  • $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
  • LATO AI Tailors AI-Powered Appointment Booking System for Custom Clothing Designer David Alan
  • BITE Data raises $3m to build AI tools for global trade compliance teams
  • Phinge Issues Notice of Possible Infringement, Investigates App-less AI Agents & Technology for Unauthorized Use of its Patented App-less Technologies
  • Huntington Learning Center of Russellville Marks 1 Year Anniversary; Extends Reduced Grant-Aligned Rates to All Students in Learning Center Services
  • CCHR Supports Call to End Coercive Psychiatry at World Mental Health Congress
  • purelyIV Expands Wellness Services with Flu/COVID Testing and Menopause Coaching & Treatment
  • WHES Retains BloombergNEF Tier 1 Ranking for Sixth Consecutive Quarter
  • U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf
  • UK Financial Ltd Confirms All 8 Mexican Gold Mines Exist — Audited and Backing UKFL's Ecosystem With Double the 2018 Gold Value

Popular on PennZone

  • New Article by Roy J. Meidinger – Examines Hidden Hidden Healthcare Kickbacks - 414
  • Mensa Foundation's New Science Program Encourages Hands-On Discovery
  • Investing in Greece: Your Definitive Real-Estate FAQ Guide
  • GitKraken Launches Insights to Help Engineering Leaders Quantify AI Impact and Improve Developer Experience
  • Blogging Pioneer Sherry Bennett Celebrates 29 Years Online - From College Blogger to Successful Entrepreneur
  • Why Philadelphia Homeowners Should Ditch Oil for Natural Gas
  • Crypto Betting Odds 2025: Bookmakers Review Analyzes Market Predictions and Year-End Price Lines
  • 'Wild Hermit Wellness' Has Achieved Bestseller Status in Just 2 Months Since Launch Of Organic Skincare Line
  • Tami Goveia Enters FabOver40, Inspiring Hollywood Legacy for Breast Cancer Cause
  • The OpenSSL Corporation and the OpenSSL Foundation Celebrate the Success of the Inaugural OpenSSL Conference in Prague

Similar on PennZone

  • Entrigue Magazine LLC Announces Strategic Media Partnership with Reewind Network LLC
  • Turbo vs. Experts: Tracking OddsTrader's AI Performance at the NFL's Midpoint
  • Outreaching.io Appoints Rameez Ghayas Usmani as CEO, Recognized as Best HARO Link Building Expert in the United States
  • Fulton County & Grow Your World Amplify Atlanta Youth Through the Youth Audio Collective
  • Allen Field Co., Inc. Components Selected for Esko ArtiosCAD 3D Component Library
  • Heritage At Manalapan - A New Luxury Single Family Home Community Coming Late 2025
  • The Lashe® Announces Exclusive November Savings for Lash and Beauty Professionals
  • Corcoran DeRonja Real Estate Welcomes Siobhán Simões to Its Growing Team
  • November is Lung Cancer Awareness Month: Screening Saves Aims to Increase Access to Lung Screenings in NC
  • Valeo Health Leads a New Era of Longevity and Preventive Health in the UAE
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us